Trial
NCT02138825
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Bayer
Collaborators
—
Condition
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Intervention
Riociguat (Adempas, BAY63-2521)
Why stopped
Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-04